11.2 Purine and Pyrimidine Synthesis, Salvage, and Gout Pathophysiology

11.2 Purine and Pyrimidine Synthesis, Salvage, and Gout Pathophysiology

Nucleotide metabolism encompasses the precise synthesis, recycling, and degradation of purine and pyrimidine nucleotides, which serve as foundational building blocks for nucleic acids (DNA and RNA), energetic cellular currency (ATP, GTP), signal transducers (cAMP, cGMP), and metabolic coenzymes (NAD+, FAD, CoA). Disruptions in nucleotide biosynthetic or salvage pathways lead to severe clinical pathologies, including metabolic hyperuricemia (gout), severe combined immunodeficiency (SCID), and neurodevelopmental syndromes.

Purine Metabolism: De Novo Biosynthesis & Salvage

Purine nucleotides (Adenine and Guanine) feature a fused double-ring structure synthesized de novo directly upon a pre-existing ribose-5-phosphate scaffold derived from the pentose phosphate pathway.

De Novo Purine Biosynthesis

1. Ribose-5-phosphate is converted to 5-phosphoribosyl-1-pyrophosphate (PRPP) by PRPP Synthetase.
2. Rate-Limiting Step: PRPP is converted to 5-phosphoribosylamine by Glutamine-PRPP Amidotransferase. This enzyme is feed-forward activated by its substrate PRPP and strongly feedback-inhibited by the purine end-products IMP, AMP, and GMP.
3. Subsequent step-by-step additions donate ring atoms: Glutamine (nitrogen), Glycine (nitrogen and carbons), Aspartate (nitrogen), $CO_2$ (carbon), and $N^{10}$-Formyl-tetrahydrofolate (carbons).
4. The first fully formed purine nucleotide intermediate is Inosine Monophosphate (IMP). IMP is subsequently converted into AMP (requiring aspartate and GTP) or GMP (requiring glutamine and ATP).

The Purine Salvage Pathway

De novo purine synthesis is highly energy-demanding, consuming at least 6 high-energy phosphate bonds per purine ring created. Consequently, tissues express recycling enzymes to salvage free purine bases released during nucleic acid turnover:

• Hypoxanthine-Guanine Phosphoribosyltransferase (HGPRT): Converts free hypoxanthine + PRPP $\rightarrow$ IMP + $PP_i$, and free guanine + PRPP $\rightarrow$ GMP + $PP_i$.
• Adenine Phosphoribosyltransferase (APRT): Converts free adenine + PRPP $\rightarrow$ AMP + $PP_i$.

Salvage enzymes conserve cellular energy and depress de novo purine synthesis by consuming PRPP and generating nucleotides that feedback-inhibit Glutamine-PRPP Amidotransferase.

Lesch-Nyhan Syndrome

• Etiology: Complete X-linked recessive deficiency of HGPRT.
• Pathophysiology: Absence of HGPRT prevents purine salvage of hypoxanthine and guanine. Unused PRPP accumulates and intensely stimulates de novo purine synthesis via Glutamine-PRPP Amidotransferase. Excess purines undergo mandatory degradation, producing massive amounts of uric acid.
• Clinical Presentation: Characterized by the high-yield clinical mnemonic HGPRT:
  • Hyperuricemia & Hyperuricuria (orange "sand" or "uric acid crystals" in infant diapers).
  • Gouty arthritis and uric acid nephrolithiasis.
  • Pissed off (severe involuntary self-mutilation: compulsive biting of lips, tongue, and fingertips).
  • Retardation (intellectual disability and cognitive impairment).
  • DysTonia (choreoathetosis, spasticity, and extrapyramidal movement disorders).

Adenosine Deaminase (ADA) Deficiency

• Etiology: Autosomal recessive deficiency of Adenosine Deaminase (ADA).
• Pathophysiology: ADA deaminates adenosine into inosine within the purine salvage pathway. In ADA deficiency, adenosine and deoxyadenosine accumulate and are phosphorylated to dATP. High intracellular levels of dATP exert potent allosteric feedback inhibition on ribonucleotide reductase, effectively halting all de novo synthesis of deoxyribonucleotides (dNTPs).
• Clinical Consequences: Without dNTPs, nuclear DNA replication and cell division cease. Proliferating T cells and B cells undergo massive apoptosis, causing Severe Combined Immunodeficiency (SCID). Infants present with recurrent, life-threatening viral, bacterial, fungal, and opportunistic infections, chronic diarrhea, failure to thrive, and absent lymph nodes and thymic shadow.

Purine Degradation & Gout Pathophysiology

Purine catabolism converges on the breakdown of purine bases into xanthine:

• Adenosine $\rightarrow$ Inosine $\rightarrow$ Hypoxanthine
• Guanosine $\rightarrow$ Guanine $\rightarrow$ Xanthine

Xanthine Oxidase (XO) is the terminal enzyme of purine degradation, catalyzing two successive oxidation steps: $\text{Hypoxanthine} \xrightarrow{\text{Xanthine Oxidase}} \text{Xanthine} \xrightarrow{\text{Xanthine Oxidase}} \text{Uric Acid}$

Uric acid is poorly soluble in aqueous plasma. When serum uric acid concentrations exceed physiological saturation ($\approx 6.8\text{ mg/dL}$), monosodium urate crystals precipitate in joints, synovial fluid, and soft tissues, triggering acute inflammation.

Gout vs. Pseudogout Differential Diagnosis

Acute inflammatory monoarthritis requires rapid differentiation via polarized light microscopy of joint aspirates:

1. Gout (Monosodium Urate Crystals):

   • Crystal Morphology: Needle-shaped intra- and extracellular crystals.
   • Birefringence: Strongly negative birefringence under polarized light with a red compensator (crystals appear yellow when parallel to the slow axis of the compensator and blue when perpendicular).
   • Clinical Features: Classically manifests as painful podagra (acute inflammation of the 1st metatarsophalangeal joint). Chronic hyperuricemia forms tophi (chalky deposits of urate crystals surrounded by foreign-body giant cell inflammation) in the Achilles tendon, pinna of the ear, and olecranon bursa.
   • Precipitating Factors: Alcohol ingestion (competes with uric acid for renal tubule excretion), high-purine diets (red meat, seafood), and thiazide/loop diuretics.

2. Pseudogout (Calcium Pyrophosphate Deposition Disease - CPPD):

   • Crystal Morphology: Rhomboid-shaped crystals.
   • Birefringence: Weakly positive birefringence under polarized light (crystals appear blue when parallel to the slow axis of the red compensator).
   • Clinical Features: Typically affects large joints (most commonly the knee). Radiographs reveal chondrocalcinosis (calcification of articular cartilage). Associated with hyperparathyroidism, hemochromatosis, and hypomagnesemia.

Pharmacological Modulation of Uric Acid

• Acute Gout Attacks: NSAIDs (indomethacin), Colchicine (inhibits microtubule polymerization, preventing neutrophil chemotaxis), and systemic glucocorticoids. Do not initiate long-term urate-lowering therapy during an acute attack, as sudden serum uric acid fluctuations worsen joint inflammation.
• Chronic Urate-Lowering Therapy:
  • Xanthine Oxidase Inhibitors: Allopurinol (purine analog competitive and suicide inhibitor of XO) and Febuxostat (non-purine selective XO inhibitor).
  • Uricosuric Agents: Probenecid (inhibits renal URAT1 anion transporters in the proximal tubule, decreasing uric acid reabsorption).

Pyrimidine Metabolism & Pharmacological Targets

Pyrimidines (Cytosine, Uracil, Thymine) feature a single heterocyclic ring. Unlike purines, the pyrimidine ring is synthesized first as free orotic acid and then attached to PRPP.

De Novo Pyrimidine Biosynthesis

1. Rate-Limiting Step: Glutamine, $CO_2$, and 2 ATP condense in the cytosol to form carbamoyl phosphate, catalyzed by Carbamoyl Phosphate Synthetase II (CPS-II).
   • Clinical Comparison: CPS-II is cytosolic, participates in pyrimidine synthesis, uses glutamine, and is activated by PRPP and inhibited by UTP. In contrast, CPS-I is mitochondrial, participates in the urea cycle, uses free $NH_4^+$, and requires N-acetylglutamate (NAG).
2. Carbamoyl phosphate condenses with aspartate to form dihydroorotate, which is oxidized to orotic acid.
3. Orotic acid is coupled to PRPP by UMP Synthase (a bifunctional cytosolic enzyme comprising orotate phosphoribosyltransferase and OMP decarboxylase) to yield Uridine Monophosphate (UMP).
4. UMP is converted to UDP and UTP. Ribonucleotide Reductase converts UDP to dUDP, which is converted to dUMP.
5. Thymidylate Synthase converts dUMP to dTMP, transferring a methyl group from $N^5,N^{10}$-Methylene Tetrahydrofolate ($N^5,N^{10}$-methylene THF), oxidising THF into Dihydrofolate (DHF).

Hereditary Orotic Aciduria

• Etiology: Autosomal recessive deficiency of UMP Synthase.
• Pathophysiology: Blockade in pyrimidine synthesis causes massive accumulation of orotic acid and depletion of pyrimidine nucleotides.
• Clinical Presentation: Infants present with severe orotic aciduria, failure to thrive, developmental delay, and megaloblastic anemia that is refractory to vitamin B12 and folate administration.
• Critical Diagnostic Differentiation: Hereditary orotic aciduria features megaloblastic anemia without hyperammonemia. In contrast, OTC deficiency exhibits hyperammonemia with urine orotic acid, but no megaloblastic anemia. Treatment of hereditary orotic aciduria involves oral uridine administration, which bypasses UMP synthase to restore pyrimidine pools.

Pharmacological Targets in Pyrimidine Biosynthesis

• 5-Fluorouracil (5-FU): Pyrimidine analog converted to 5-dFUMP, which covalently binds and inhibits Thymidylate Synthase, blocking dTMP production ("thymineless death" in cancer cells).
• Methotrexate (Human), Trimethoprim (Bacterial), Pyrimethamine (Protozoal): Competitively inhibit Dihydrofolate Reductase (DHFR), preventing conversion of DHF back to active THF. This depletes $N^5,N^{10}$-methylene THF, blocking dTMP synthesis and purine de novo synthesis.

Purine vs. Pyrimidine Metabolic Comparison